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Abstract:Mesonephric adenocarcinoma (MNAC) is a rare tumor of
the female genital tract mainly occurring in the uterine cervix. To
date, only a few cases of MNAC arising from of the uterine body
(UB-MNAC) have been reported. The clinicopathologic and mo-
lecular characteristics of UB-MNAC remain unknown. In this study,
we investigated the clinical, histopathologic, immunohistochemical,
and genetic features of UB-MNAC. In total, 11 cases were included.
Six patients developed metastatic disease, most commonly in lungs
(5/6). Histopathologically, UB-MNAC was characterized by an ad-
mixture of tubular, glandular, papillary, retiform, glomeruloid, sex
cord-like, and comedonecrosis-like architectural patterns. Three ad-
verse pathologic characteristics, including advanced International
Federation of Gynecology and Obstetrics stage, high mitotic activity,
and presence of lymphovascular the invasion, were independent
factors predicting the development of metastasis. All cases were
positive for GATA-binding protein 3 and paired box 2 expression
and showed wild-type p53, patchy p16, and preserved PTEN
expression, as indicated by immunohistochemistry. Next-generation
sequencing using 12 samples (11 primary tumors and 1 metastatic
tumor) revealed 42 single nucleotide variations in 16 genes, mostly in
KRAS (10/12) and ARID1A (9/12). Copy number variation was
found in 16 genomic regions, and consisted of 57 gains and 10 losses,
with 1q gain (11/12) being the most prevalent. In conclusion,
UB-MNAC displays an aggressive biological behavior, with a ten-
dency to metastasize to the lungs. Adverse pathologic characteristics
reﬂect the aggressive nature of UB-MNAC. Distinct molecular
features of UB-MNAC include frequent somatic mutations ofKRAS
and ARID1A and gain of 1q.
Key Words: uterine body, mesonephric adenocarcinoma, metastasis,
next-generation sequencing, KRAS, ARID1A, 1q gain
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Mesonephric adenocarcinoma (MNAC) is a rare malig-nant tumor that originates from mesonephric remnants
of the female genital tract.1 MNAC is histopathologically
characterized by a combination of diverse growth patterns
showing tubular, glandular, papillary, retiform, and glomer-
uloid architecture, and a has a distinctive immunophenotype.2
MNAC exhibits positive immunoreactivity for GATA-
binding protein 3 (GATA3), paired box 2 (PAX2), and CD10,
and negative reactivity for hormonal receptors.3–6 Meso-
nephric remnants are typically located in the cervical stroma
and adjacent to the ovaries, fallopian tube, and broad
ligament, although they may rarely occur in the vaginal wall or
myometrium.7 Previous studies have documented that meso-
nephric remnant in any location can be the origin of MNAC.
Although most cases of MNAC are found in the uterine cervix
(UC),2,8,9 several cases of MNAC arising from the ovaries,
vagina, and uterine corpus have been reported.5,10–19
The pathogenesis of MNAC remains unknown.MNAC
shows preserved phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) expression, wild-type p53 expression
pattern, and nondiffuse p16 expression, indicating that this rare
tumor exhibits immunohistochemical and molecular features
different from those of endometrial endometrioid and serous
carcinoma and usual-type endocervical adenocarcinoma. A
recent study that used next-generation sequencing (NGS) for
targeted genomic proﬁling reported that the majority of
MNAC examined harbored KRAS mutation,20 suggesting
that KRAS mutation is involved in MNAC development.
Most patients with MNAC of the UC(UC-MNAC)
present at International Federation of Gynecology and
Obstetrics (FIGO) stage I. Distant metastases at initial
diagnosis are detected in ∼5% of UC-MNAC patients.9
Thirty-two percent of FIGO stage I UC-MNAC patients
develop recurrence even after curative resection.9 This rate
of recurrence is substantially higher than that of FIGO stage
I cervical squamous cell carcinoma (11.0%) and usual-type
endocervical adenocarcinoma (16.0%),21 suggesting that
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patients with UC-MNAC have a worse prognosis than
those with more common types of cervical carcinoma.
Because of the limited number of cases reported, less is
known regarding the clinical outcomes of MNAC arising
from the uterine body (UB-MNAC). Most publications on
UB-MNAC are individual case reports.10–18 Although some
case series have described the clinicopathologic character-
istics of MNAC, they dealt with only a few cases of
UB-MNAC.3,6,20,22
We recently identiﬁed some cases of UB-MNAC in
postmenopausal women who developed distant metastases.
Upon a thorough literature review, we recognized that
approximately half of the patients with UB-MNAC develop
metastatic disease. This ﬁnding led us to investigate the clinical
outcomes of UB-MNAC diagnosed in our institution. In this
study, we analyzed the clinical characteristics, histopathologic
features, and immunohistochemistry of UB-MNAC. Using
NGS technology, we investigated the molecular genetic
alterations associated with UB-MNAC.
MATERIALS AND METHODS
Case Selection
Following approval (4-2017-0837) by the Institutional
Review Board at the Severance Hospital (Seoul, Republic of
Korea), the pathology database was queried for all cases of
UB-MNAC between 2012 and 2017. The inclusion criteria
were: (1) histopathologically conﬁrmed MNAC; (2) no in-
volvement of the UC and low uterine segment; and (3) tumor
epicenter within the myometrium of the UB. Eleven cases of
UB-MNAC were included in this study. For each case, all
slides were available for review.
Medical Record Review
All patients were treated and monitored at the Depart-
ment of Obstetrics and Gynecology, Severance Hospital
(Seoul, Republic of Korea). We thoroughly reviewed patients’
medical records, pathology reports, and gross photographs.
Clinical details, including age at initial diagnosis, presentation
of symptoms and/or signs, serum cancer antigen (CA)-125
level, preoperative endometrial curettage diagnoses, surgical
treatment, FIGO stage, postoperative treatment, response
to chemotherapy and/or radiation therapy, development of
recurrence and/or metastasis, progression-free and overall
survival, and current status were examined. The pathologic
characteristics reviewed included tumor size, border, architec-
tural pattern, and invasion depth; presence of sarcomatous
component; coagulative tumor cell necrosis and lymphovas-
cular invasion; degree of nuclear atypia; and mitotic count per
10 high-power ﬁelds.
Pathologic Examination
Formalin-ﬁxed, parafﬁn-embedded (FFPE) blocks
of surgical resection specimens were cut into 4-μm sections
and stained with hematoxylin and eosin. Two independent
pathologists specialized in gynecologic oncology examined
all available stained slides by routine light microscopy and
selected the most representative FFPE block for immuno-
histochemical staining and NGS analyses.
Immunohistochemistry
The FFPE tissue sections were deparafﬁnized in xylene
and rehydrated through graded ethanol series. Im-
munohistochemical staining was conducted using the Ventana
Benchmark XT automated staining system (Ventana Medical
Systems, Tucson, AZ) or Dako Omnis (Dako, Carpinteria,
CA), according to the manufacturer’s recommendations.
Antigen retrieval was achieved using Cell Conditioning Sol-
ution (CC1; Ventana Medical Systems) or EnVision FLEX
Target Retrieval Solution, High pH (Dako). The sections
were subsequently incubated with primary antibodies against
calretinin (1:100, polyclonal; Cell Marque, Rocklin, CA),
CD10 (1:50, clone 56C6; Novocastra, Leica Biosystems,
Newcastle Upon Tyne, UK), cytokeratin 7 (1:100, clone
OV-TL 12/30; Dako), estrogen receptor (ER, 1:150, clone
6F11; Novocastra), GATA3 (1:150; Cell Marque), p16 (pre-
diluted, clone E6H4; Ventana Medical Systems), p53 (1:300,
clone DO-7; Novocastra), PAX2 (1:1000, clone EP3251;
GeneTex, Irvine, CA), progesterone receptor (PR; 1:100;
clone 16; Novocastra), and PTEN (1:100, clone D4.3; Cell
Signaling Technology, Danvers, MA). After chromogenic
reaction using an ultraView Universal DAB Detection Kit
(Ventana Medical Systems) or an EnVision FLEX /HRP Kit
(Dako), the slides were counterstained with hematoxylin. The
p53 immunostaining pattern was interpreted as a missense-
mutation, nonsense-mutation, or wild-type pattern when p53
expression was diffuse and strong (>60% of tumor cell nu-
clei), absent (<5%), or focal and weakly positive, respectively.
The p16 immunostaining pattern was interpreted as positive
(diffuse) when p16 expression was continuous and strong,
nuclear or nuclear plus cytoplasmic staining. All other p16
immunostaining patterns, described as focal nuclear staining
or wispy, blob-like, puddled, or scattered cytoplasmic stain-
ing, were interpreted as negative (patchy).23
Next-generation Sequencing
Genomic DNA was extracted using a QIAamp DNA
FFPE Tissue Kit (Qiagen, Valencia, CA). Using genomic
DNA, coding exons and their ﬂanking regions of 82 genes
(Supplementary Table 1, Supplementary Digital Content 1,
http://links.lww.com/PAS/A567) were enriched using the
SureSelectXT Reagent Kit (Agilent Technologies, Santa
Clara, CA). The products were sequenced on a HiSeq 2500
System (Illumina, San Diego, CA) using paired-end reads. The
reads were aligned to a reference genome sequence (version
hg19) obtained from the University of California Santa Cruz
Genome Browser database (https://genome.ucsc.edu/),24 and
duplicate reads were removed. Burrows-Wheeler Aligner-
MEM (http://bio-bwa.sourceforge.net/), SAMtools (http://
samtools.sourceforge.net/), Picard Tools (http://broadinstitute.
github.io/picard/), and GATK (https://software.broadinstitute.
org/gatk/) were used for sorting Sequence Alignment Map/
Binary Alignment Map ﬁles, duplicate marking, and local
realignment, respectively. Local realignment and base recali-
bration were carried out using dbSNP (www.ncbi.nlm.nih.gov/
projects/SNP/), Mills indels,25 HapMap, and Omni. Single
nucleotide variants (SNVs) and insertions and deletions (indels)
were identiﬁed using MuTect (http://archive.broadinstitute.org/
cancer/cga/mutect) and Pindel (http://gmt.genome.wustl.edu/
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TABLE 1. Clinical Characteristics of UB-MNAC
Case
Year
Reported
Age
(y)
Presenting
Symptom/Sign
CA-125
(U/mL)
Preoperative
Diagnosis
Through EM
Curettage
Surgical
Treatment
FIGO
Stage Postoperative Clinical Course
PFS
(mo)
OS
(mo)
Current
Status
1 199510 58 Polyuria WNL NA TH+BSO IB No postoperative treatment
Paraaortic and mediastinal
LN metastasis
CTx (cisplatin+cyclophosphamide)
4 8 DOD
2 200111 33 LAP 47.0 NA TH+BSO+PLND IB RTx
No speciﬁc event
NA 8 NED
3 200312 33 LAP 41.0 NA TH+BSO+PLND
+PALND
IB RTx
Lung, abdomen, and perihepatic LN
metastasis and elevated CA-125
CTx (carboplatin+paclitaxel, 12 cycles)
Partial response
10 22 AWD
4 200413 37 Vaginal bleeding NA NA TH+BSO IB No postoperative treatment
No speciﬁc event
NA 45 NED
5 200614 81 Vaginal bleeding 55.0 MNAC TH+BSO+PLND
+PALND
IB No postoperative treatment
No speciﬁc event
NA 9 NED
6 200815 73 Multiple pulmonary
nodules
WNL NA TH+BSO IVB CTx (carboplatin+paclitaxel)
Increased size of lung metastasis
and abdominal recurrence
CTx (carboplatin+paclitaxel)
Stable disease
6 28 AWD
7 201416 55 Vaginal bleeding NA MNAC TH+BSO+PLND IB No postoperative treatment
No speciﬁc event
NA 7 NED
8 201416 62 Vaginal bleeding NA MNAC TH+BSO+PLND IB No postoperative treatment
No speciﬁc event
NA 1 NED
9 201617 66 Vaginal bleeding WNL EC TH+BSO+PLND IB No postoperative treatment
No speciﬁc event
NA 2 NED
10 201618 55 Vaginal bleeding 163.8 AC with
sarcomatous
feature
TH+BSO+PLND II CTx (cisplatin+paclitaxel, 4 cycles)
Mediastinal LN metastasis, abdominal
recurrence, and elevated CA-125
CTx (pirarubicin+cisplatin+ifosfamide)
8 12 DOD
11 201618 62 Vaginal bleeding WNL MNAC TH+BSO+PLND IIIC RTx+CTx (cisplatin+docetaxel)
No speciﬁc event
NA 16 NED
12 2017 58 Vaginal bleeding 65.0 EC TH+BSO+PLND
+PALND
IIIB RTx+CTx (carboplatin+paclitaxel, 3 cycles)
Lung metastasis
CTx (carboplatin+paclitaxel, 3 cycles)
Stable disease
50 56 AWD
13 2017 55 Vaginal bleeding WNL NA TH+BSO IVB RTx+CTx (carboplatin+paclitaxel, 6 cycles)
Partial response CTx (carboplatin+paclitaxel,
6 cycles)
Increased size of lung metastasis and elevated
CA-125
CTx (carboplatin+paclitaxel, 9 cycles)
Stable disease
14 21 AWD
14 2017 54 Vaginal bleeding WNL NA TH+BSO IIIB RTx+CTx (carboplatin+paclitaxel, 6 cycles)
Lung metastasis
CTx (doxorubicin+cisplatin
+cyclophosphamide, 3 cycles)
Stable disease
9 20 AWD
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packages/pindel/), respectively. ANNOVAR (http://annovar.
openbioinformatics.org/) was used to annotate the detected
variants. Any SNV present at >0.1% in Exome Variant
Server (https://evs.gs.washington.edu/) or dbSNP was ﬁltered.
The variants present in the Catalogue of Somatic Mutations
in Cancer (http://evs.gs.washington.edu/EVS/) were reviewed.
Copy number variation (CNV) log2 ratios were generated
using a depth of coverage normalized against the median from
a panel of normal uterine tissues.
Literature Review
The Medline database was thoroughly searched
using the PubMed retrieval service (www.ncbi.nlm.nih.
gov/pubmed/). The key words used were “mesonephric
adenocarcinoma,” “mesonephric carcinoma,” “endometrium,”
“uterine corpus,” and “uterine body.”
Statistical Analysis
The χ2 test or Fisher exact test was used to examine
whether the pathologic characteristics are associated with
the development of metastasis. Multivariate logistic re-
gression with a backward stepwise elimination method
was used to identify independent predictors of metastatic
disease. Statistical analyses were carried out using PASW
Statistics for Windows (version 18.0; IBM, Armonk, NY).
Statistical signiﬁcance was deﬁned as a P-value <0.05.
RESULTS
Clinical Characteristics of UB-MNAC
We identiﬁed 11 cases of UB-MNAC in our institu-
tional pathology database and 11 reported cases through a
thorough literature search. Table 1 summarizes the clinical
characteristics. Of our 11 patients (cases 12 to 22), 10 patients
had presented with vaginal bleeding. Patient age ranged
from 52 to 70 years (median, 59 y). All patients were
postmenopausal women. Two patients showed increased
serum CA-125 at initial diagnosis. Endometrial curettage was
carried out in 8/11 patients. In these patients, histopathologic
diagnoses were endometrioid carcinoma (5/8), MNAC (2/8),
and carcinosarcoma (1/8). All patients underwent total
hysterectomy and bilateral salpingo-oophorectomy with or
without pelvic or para-aortic lymph node dissection.
The FIGO stage was IA in 3/11, IB in 3/11, III in
4/11, and IV in 1/11 patients. Metastasis was detected in
6/11 patients, either initially (2/6) or during the follow-up
period (4/6). The metastatic sites were lungs (4/6), regional
lymph nodes (1/6), and lungs and regional lymph nodes
(1/6). Four of the 5 patients with a FIGO stages III to
IV tumor received carboplatin/paclitaxel-based chemo-
radiation therapy, and the remaining patient received
carboplatin/paclitaxel-based chemotherapy. However,
4/5 patients who received chemoradiation therapy (3/4)
or chemotherapy (1/4) experienced disease progression.
Three patients with FIGO stage I tumor did not receive
any additional therapy, whereas the remaining 3/6 patients
received postoperative radiation therapy (1/6) or carbo-
platin/paclitaxel-based chemotherapy (2/6). One patient15
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who received chemotherapy developed metastatic disease
after surgery.
Overall, 5/11 patients experienced disease progression
after surgery. Progression-free survival ranged from 8
to 50 months (median, 10mo). Elevated serum CA-125
accompanied disease progression in 1/5 patients. Four of
the 5 patients with progressive disease received carboplatin/
paclitaxel-based chemotherapy, and the remaining patient
was treated with combination chemotherapy with cisplatin,
doxorubicin, and cyclophosphamide. These patients
showed stable disease for 4 to 11 months (median, 7 mo)
after the chemotherapy had begun. The remaining 6/11
patients showed no evidence of tumor recurrence during
the follow-up period (range, 3 to 12mo; median, 8.5 mo).
All patients are currently alive.
Pathologic Characteristics of UB-MNAC
Table 2 summarizes the pathologic characteristics of
UB-MNAC. The largest tumors were 1.5 to 7.4 cm
(median, 3.7 cm). Grossly, they presented as single, solid,
or solid and cystic masses and were typically located in the
lateral or posterior wall of the UB. Four of the 11 tumors
protruded into the endometrial cavity, with exophytic or
polypoid appearance. The surfaces of the protruded
portions were either ulcerated (2/4) or smooth (2/4). Five
tumors with an ill-deﬁned border inﬁltrated deeply into
the uterine wall, whereas the remaining 6/11 tumors had a
well-deﬁned border. The cut tumor surface was gray or
yellow-to-tan (Fig. 1). Seven tumors contained a variable
amount of coagulative necrosis and hemorrhage. Small
uterine leiomyomata (3/11) and ovarian hemorrhagic cysts
(2/11) were also noted.
Histopathologically, the tumors exhibited diverse ar-
chitectural patterns, with various combinations of tubular,
glandular, papillary, retiform, glomeruloid, sex cord-like,
and comedonecrosis-like patterns. These patterns frequently
merged into each other. Tubular and glandular patterns
were predominant in all cases. The tubules were small,
round, uniform, and closely packed, and accompanied
by little intervening stroma, producing a back-to-back
appearance. They were lined by a single layer of cuboidal or
ﬂattened epithelial cells and sometimes possessed intra-
luminal hyaline-like eosinophilic material (Fig. 2A). The
glandular pattern closely resembled that of endometrioid
carcinoma (Fig. 2B). These glands varied in size and often
exhibited intraluminal villous projections, which were lined
by several layers of columnar epithelial cells. Some glands
were cystically dilated (Fig. 2C). There were irregular-
shaped glandular lumina containing papillary cellular buds.
Intraluminal ﬂoating papillary tufts and micropapillae were
morphologically similar to those of serous carcinoma
(Fig. 2D). The budding papillae were lined by a single
layer of 10 to 20 cuboidal epithelial cells and contained
ﬁbrous or ﬁbrovascular cores. Discohesive tumor cells
within dilated glandular lumina were also observed. In
8/11 cases, there were round-to-ovoid glands showing
complex cribriform architectures within the lumina. These
cribriform structures with a single point or 2 points of
attachment to the outer glandular epithelium and the
nonadherent portion producing crescent-like empty spaces
mimicked a renal glomerulus (glomeruloid pattern; Fig. 2E).
We found 2/11 cases showing abundant necrotic debris,
which ﬁlled the dilated glandular lumina and were
surrounded by viable tumor cells arranged in a papillary,
cribriform, or solid pattern. These morphologic features
resembled comedonecrosis observed in situ in ductal
carcinoma of the breast (comedonecrosis-like pattern;
Fig. 2F). The retiform pattern was a relatively minor
component, but was, at least focally, present in all cases. It
was characterized by elongated, slit-like branching tubules
and intraluminal papillary projections with hyalinized
ﬁbrous cores. The papillae were lined by a single or
several layers of cuboidal or columnar epithelial cells. The
slit-like tubules were surrounded by a reactive ﬁbrous
stroma (Fig. 2G). The sex cord-like pattern, which was
observed in 2/11 cases, consisted of branching cords and
trabeculae of tumor cells. The cords and trabeculae were
separated by acellular, myxoid, or edematous stroma
containing small, arborizing blood vessels (Fig. 2H).
Cytopathologically, most tumor cells in all the pat-
terns had vesicular and angulated nuclei, and contained
scant, pale-to-eosinophilic cytoplasm. They lacked a
hobnail appearance, prominent cytoplasmic clearing, and
squamous or mucinous differentiation. The degree of nu-
clear atypia was assessed based on nuclear pleomorphism,
coarse chromatin, and the presence of macronucleoli.
Seven tumors exhibited mild-to-moderate nuclear atypia,
and the remaining 4/11 tumors displayed severe nuclear
atypia. Mitotic counts ranged from 4 to 23/10 high-power
ﬁelds (median, 15/10 high-power ﬁelds; Fig. 3A) and were
most numerous in the glandular pattern. Seven cases
showed areas of coagulative tumor cell necrosis (Fig. 3B).
Among our 11 cases of UB-MNAC, 4 exhibited the
sarcomatous component, which consisted of solid sheets of
closely packed, oval-to-spindle cells and resembled non-
speciﬁc spindle cell sarcoma (Fig. 3C). In 3/4 cases, the
tubules and glands partly merged with areas of the
sarcomatous component. The sarcomatous component
accounted for ∼10% to 20% the tumor. One of these 3
cases displayed a heterologous component in the form of
chondrosarcomatous differentiation. The remaining of the
4 cases exhibited diffuse sheets of uniform, round-to-oval
cells with scant cytoplasm that resembled those of low-
grade endometrial stromal sarcoma. Nuclear atypia was
mild-to-moderate in 3/4 cases and severe in 1/4 case
(Fig. 3D). Mitotic counts in the sarcomatous component
ranged from 8 to 15/10 high-power ﬁelds.
Histopathologic analysis of tumor topography re-
vealed that the endomyometrium was involved in all cases,
except 1. Parametrial extension was identiﬁed in 4/11
cases; all of these tumors had an ill-deﬁned border. Peri-
tumoral stroma in both of pushing borders and inﬁltrative
borders was scanty cellular and desmoplastic. Seven cases
had frequent lymphovascular tumor cell emboli (Fig. 3E).
Histopathologic examination results of metastatic tumor
tissues were available for 3 cases. The metastatic tumors
exhibited carcinomatous component of glandular pattern
only (Fig. 3F). In all cases, neither mesonephric remnant
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TABLE 2. Pathologic Features of UB-MNAC
Histopathologic Finding
Gross Finding Architecture
Case
Tumor
Size
(cm)
Tumor
Border Tubular Glandular Papillary Retiform Glomeruloid
Sex
Cord-
like
Comedonecrosis-
like
Sarcomatous
Component
Invasion
Depth
FIGO
Stage
Nuclear
Atypia CTCN Mitosis LVI
1 14.0 Ill-
deﬁned
Present Present Present Absent Absent Present NA Present
(spindle cell)
SM to
DM
IB Severe Present Frequent Present
2 8.0 Well-
deﬁned
Present Present Absent Present Absent Absent NA Present
(spindle cell)
SM to
DM
IB Moderate Present Up to 3/
HPF
NA
3 8.0 Ill-
deﬁned
Present Present Absent Present Absent Absent NA Present SM to
DM
IB NA NA NA NA
4 3.5 Well-
deﬁned
Present Present Absent Present Absent Absent NA Present
(ESS-like)
EM to
DM
IB Mild to
moderate
NA 2/10
HPFs
Absent
5 3.7 Well-
deﬁned
Present Present Present Absent Absent Absent NA Absent EM to
DM
IB NA NA NA NA
6 8.0 Well-
deﬁned
Present Present Present Present Present Absent NA Absent EM to
DM
IVB Mild Present 27/10
HPFs
Present
7 3.5 Well-
deﬁned
Present Present Absent Present Present Present NA Present
(spindle cell)
SM to
DM
IB NA NA NA NA
8 8.0 Well-
deﬁned
Present Present Absent Present Present Present NA Present
(spindle cell)
EM to
DM
IB NA NA NA NA
9 2.7 Well-
deﬁned
Present Present Present Present Present Absent NA Absent EM to
DM
IB Mild to
moderate
Absent 10/10
HPFs
NA
10 3.5 NA NA NA NA NA NA NA NA Present SM to
DM
II NA NA NA Absent
11 5.8 NA NA NA NA NA NA NA NA Present EM to
DM
IIIC NA NA NA Absent
12 2.3 Ill-
deﬁned
Present Present Present Present Absent Absent Absent Absent EM to
PM
IIIB Mild to
moderate
Present 15/10
HPFs
Present
13 7.4 Well-
deﬁned
Present Present Present Present Present Absent Absent Absent EM to
DM
IVB Mild to
moderate
Present 23/10
HPFs
Present
14 4.3 Ill-
deﬁned
Present Present Present Present Present Present Present Present
(spindle cell)
EM to
PM
IIIB Severe Present 19/10
HPFs
Present
15 4.1 Ill-
deﬁned
Present Present Present Present Present Absent Absent Present
(spindle cell)
EM to
SM
IA Severe Present 21/10
HPFs
Present
16 2.3 Well-
deﬁned
Present Present Present Present Present Present Absent Present
(ESS-like)
EM to
SM
IA Mild to
moderate
Absent 4/10
HPFs
Absent
17 5.7 Ill-
deﬁned
Present Present Present Present Present Absent Present Absent SM to
PM
IIIC Severe Present 19/10
HPFs
Present
18 2.6 Well-
deﬁned
Present Present Present Present Present Present Absent Absent EM to
DM
IB Mild to
moderate
Absent 8/10
HPFs
Absent
19 2.2 Well-
deﬁned
Present Present Present Present Present Present Absent Absent EM to
DM
IB Mild to
moderate
Absent 7/10
HPFs
Present
20 3.7 Well-
deﬁned
Present Present Present Present Absent Absent Absent Absent EM to
DM
IB Severe Present 5/10
HPFs
Absent
21 4.8 Ill-
deﬁned
Present Present Present Present Absent Absent Absent Present
(spindle cell)
EM to
PM
IIIC Mild to
moderate
Present 17/10
HPFs
Present
22 1.5 Well-
deﬁned
Present Present Present Present Absent Absent Absent Absent EM to
SM
IA Mild to
moderate
Absent 6/10
HPFs
Absent
CTCN indicates coagulative tumor cell necrosis; DM, deep myometrium; EM, endometrium; ESS, endometrial stromal sarcoma; HPFs, high-power ﬁelds; LVI, lymphovascular invasion; NA, not applicable; PM,
parametrium; SM, superﬁcial myometrium.
Am
J
Surg
Pathol

Volum
e
43,
N
um
ber
1,
January
2019
C
linicopathologic
and
M
olecular
Features
of
U
B-M
N
AC
C
opyright
©
2017
T
he
A
uthor(s).
P
ublished
by
W
olters
K
luw
er
H
ealth,
Inc.
w
w
w
.ajsp.com
| 17
nor mesonephric hyperplasia was identiﬁed in the adjacent
myometrium. The following coexistent gynecologic lesions
were identiﬁed: adenomyosis (6/11), leiomyoma (3/11),
and ovarian endometriosis (2/11).
Association Between Metastasis and Pathologic
Characteristics of UB-MNAC
We further examined whether the above-mentioned
pathologic characteristics are associated with the develop-
ment of metastasis. Six characteristics, including large tumor
size (>4 cm), ill-deﬁned tumor border, advanced FIGO
stages (III to IV), presence of coagulative tumor cell necrosis,
high mitotic activity (>10/10 high-power ﬁelds), and pres-
ence of lymphovascular invasion, were signiﬁcantly asso-
ciated with the development of metastasis (Table 3). In
multivariate analysis, advanced FIGO stage, high mitotic
activity, and lymphovascular invasion were found to be
independent factors predicting the development of metastasis
(Table 3). The remaining features, including architectural
pattern, extrauterine extension, deep invasion, severe nuclear
atypia, and presence of sarcomatous component, were not
signiﬁcantly associated with metastasis. Six patients who
developed metastasis had 4 or more of adverse characteristics
in various combinations (range, 4 to 6), whereas <3 of
adverse characteristics (range, 0 to 2) were found in 5 patients
without metastasis.
Immunophenotype of UB-MNAC
Table 4 summarizes the results of immunohistochemical
staining. All (11/11) cases were positive for GATA3 (Fig. 4A),
although both the extent and intensity of GATA3 positivity
varied. Eight cases showed diffuse GATA3 immunoreactivity
with moderate to strong intensity, whereas the remaining 3/11
cases displayed focal GATA3 expression, also with variable
intensity. Areas showing sarcomatous component, as
evidenced by spindled growth, present in 4 cases were
consistently negative for GATA3 in contrast to more well-
differentiated areas of these tumors with tubular or papillary
architecture. All (11/11) cases examined displayed diffuse
PAX2 immunoreactivity (Fig. 4B). In contrast to the weak-to-
moderate staining intensity of PAX2 in non-neoplastic
endometrial glandular epithelium, staining intensity in the
tumor cells was uniformly strong in all cases examined. PTEN
expression was preserved in all cases examined (11/11;
Fig. 4C). ER (0/11; Fig. 4D) and PR (0/11; Fig. 4E)
expression was negative in all cases examined. The tumor cells
exhibited wild-type p53 immunostaining pattern (Fig. 4F) and
negative (patchy) p16 immunoreactivity in both the nuclei and
the cytoplasm (Fig. 4G). CD10 immunostaining revealed a
luminal expression pattern in 11/11 cases (Fig. 4H). Calretinin
expression was focally positive in 3/11 cases (Fig. 4I). The
tumor cells demonstrated diffuse and strong membranous
cytokeratin 7 immunoreactivity.
Genetic Alterations Associated With UB-MNAC
The 12 tumor-tissue samples subjected to NGS
consisted of 11 primary UB-MNACs and 1 metastatic
UB-MNAC. The average number of unique, high-quality,
aligned reads was 8,592,849 (range, 5,458,235 to 12,852,702),
with an average target coverage of 1969× (range, 787 to
3211×). Overall, 98.87% of the targeted sequences had at
least 30× target base coverage across the samples.
Forty-two SNVs were identiﬁed in 16 genes and con-
sisted of 36 missense mutations, 3 frameshift mutations, and
3 nonsense mutations (Fig. 5). Twenty-two of these 42 SNVs
had been previously reported as somatic mutations in other
tumors. The most commonly detected SNV in UB-MNAC
was activating KRAS mutation (10/12), including G12V
(6/12), G12C (2/12), and G12D (2/12). The second most
common SNV was ARID1A mutation (9/12), including
T294P (6/12), Q288P (2/12), and Q287Pfs (1/12). Recurrent
somatic mutation of PTCH2 was identiﬁed in 4/12 cases.
CNV was found in 16 genomic regions and included
57 gains and 10 losses (Fig. 6). Most of the CNVs were
arm-level alterations involving > 2 genes. CNV involving
a single gene was detected in 6 regions (2q gain, 3q loss, 5p
gain, 6q gain, 16q gain, and 19p gain). Eleven cases had
gain of 1q, and 2 of the cases with 1q gain also had loss of
1p. Other recurrent CNVs included 9p gain (7/12), 20q
gain (7/12), 12q gain (6/12), 6q gain (4/12), 10q gain (4/12),
3q loss (3/12), 5p gain (3/12), 7q gain (3/12), 19p gain
(3/12), and gain of chromosome 2 (3/12). Gain of 10q was
detected exclusively in 3 cases with metastasis.
Of note, primary (case 13A) and metastatic (case 13B)
tumors exhibited identical mutations in KRAS and ARI-
D1A and shared the same CNV pattern. Additional PTEN
FIGURE 1. Gross findings of UB-MNAC. A and B, The tumor protrudes into the endometrial cavity, without grossly definite
myometrial invasion. C, The tumor deeply infiltrates into the myometrium (lower panel). The cut surface of the tumor closely
resembles that of intramural leiomyoma (upper panel). D, The tumor infiltrates the entire uterine wall.
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FIGURE 2. Histopathologic findings of UB-MNAC: architectural patterns. A, Tubular pattern. The tubules are lined by a single layer
of cuboidal cells and possess intraluminal eosinophilic material (inset). B, Glandular pattern. The endometrioid-like glands are lined
by several layers of columnar epithelium. C, Glandular pattern. Some glands are cystically dilated and irregular in shape. D, Papillary
pattern. Note the intraluminal papillary projections and floating micropapillary tufts (inset). E, Glomeruloid pattern. Dilated glands
contain intraluminal cribriform structures with 2 points of attachment, resembling a renal glomerulus. F, Comedonecrosis-like pattern
showing necrotic debris centrally located in the dilated glandular lumina and surrounded by tumor cells arranged in a papillary,
cribriform, or solid pattern. G, Retiform pattern showing elongated, slit-like branching tubules. H, Sex cord-like pattern showing
anastomosing trabeculae and cords of tumor cells with background of edematous or myxoid stroma.
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mutation (D268E) was detected in metastatic tumor only,
indicating that PTEN mutation is a relatively late event in
the sequence of genetic alterations in UB-MNAC.
DISCUSSION
This study aimed to comprehensively analyze the
clinicopathologic characteristics of and molecular genetic
FIGURE 3. Histopathologic findings of UB-MNAC: adverse pathologic characteristics and metastasis. A, High mitotic activity. Blue
circles indicate mitotic figures. B, Coagulative tumor cell necrosis. C, Sarcomatous component resembling nonspecific spindle cell
sarcoma. D, Sarcomatous component showing severe nuclear pleomorphism. Note large, bizarre nuclei with intranuclear vacuoles
(right upper and lower corners). E, Lymphovascular invasion. F, Histopathologic examination of pulmonary metastatic lesion reveals
the carcinomatous component in the glandular pattern only.
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alterations associated with UB-MNAC. Eleven cases of UB-
MNAC have been reported to date (Table 1).10–18 At the time
of diagnosis, the FIGO stage was IB in 8, II in 1, III in 1, and
IV in 1 patients. Six patients with FIGO stage I tumor received
no additional therapy after surgery, whereas the remaining
2/8 patients received postoperative radiation therapy. Three
patients with FIGO stage I tumor developed metastatic
disease after surgery. Two patients with FIGO stages II to
IV who received carboplatin/paclitaxel-based chemotherapy
showed disease progression, and the other patient who received
cisplatin/docetaxel-based chemoradiation therapy showed no
evidence of disease. Overall, 4/11 patients experienced disease
progression after surgery. Progression-free survival ranged
from 4 to 10 months (median, 7mo). The data of these
previously reported cases are in agreement with our results in
view of clinical presentation, age distribution, and disease
progression rate. The most common presenting symptom was
vaginal bleeding (7/11). Patient age ranged from 33 to 81 years
(median, 58 y). Two (25.0%) and 1 (16.6%) of the 8 reported
and 6 of our patients with FIGO stage I disease, respectively,
experienced progressive disease. Similarly, progression in
FIGO stages II to IV disease was observed in 2/3 (66.6%)
previously reported cases and 4/5 (80%) of our cases.
Among our 11 cases and the reported 11 cases of
UB-MNAC, half (11/22) of the patients developed
metastatic disease. We found that the metastatic rate of
UB-MNAC (50.0%) was substantially higher than that
reported for UC-MNAC, which shows metastatic disease
in ∼10% of the cases.8,9 UB-MNAC presented with more
advanced FIGO stages (III to IV) than does UC-MNAC
(36.3% vs. 5%).8,9 Furthermore, disease progression in
UB-MNAC patients mainly manifested as distant meta-
stasis. Pulmonary metastasis is a very unusual event in
endometrial carcinoma.26,27 However, in this study,
UB-MNAC most commonly metastasized to the lungs.
The reason for frequent pulmonary involvement of
UB-MNAC is unclear, but our observation of vascular
invasion in the peritumoral areas supports hematogenous
spread as one of the possible mechanisms. Our ﬁndings
warrant caution in the clinical surveillance and therapeutic
strategies for UB-MNAC, considering its high metastatic
potential and frequent pulmonary involvement.
The main differential diagnosis of UB-MNAC is
endometrial endometrioid carcinoma, as UB-MNAC pre-
dominantly consists of tubular and glandular architectural
patterns. Features in favor of UB-MNAC include lack of
endometrial hyperplasia or endometrioid intraepithelial
neoplasia in the background, absence of squamous differ-
entiation and mucin, and identiﬁcation of myometrial-
based lesions. Positive immunoreactivity for GATA3 and
PAX2 and negativity for hormone receptors ER and PR
support the diagnosis of UB-MNAC.5,28 When a papillary
architectural pattern in association with high-grade nuclear
atypia is observed, endometrial serous carcinoma should be
considered in the differential diagnosis. The presence of
intraluminal eosinophilic colloid-like material, wild-type
p53 immunostaining pattern, patchy p16 expression, and
positive GATA3 expression are features supportive of
UB-MNAC.29 The occurrence of admixtures of architec-
tural patterns sometimes renders it difﬁcult to differentiate
UB-MNAC from endometrial clear cell carcinoma. Clear
cell carcinoma typically exhibits wild-type p53 immuno-
staining pattern, patchy p16 expression, and negative
staining for ER and PR.30 However, the absence of hobnail
cells, a prominent clear cell change, and eosinophilic stromal
TABLE 3. Association Between Metastasis and Pathologic
Characteristics of UB-MNAC
Univariate
Metastasis Multivariate
Characteristics Present Absent P P
Tumor size
> 4 cm 5 (100.0) 0 0.015* 0.102
≤ 4 cm 1 (16.7) 5 (83.3)
Tumor border
Ill-deﬁned 5 (100.0) 0 0.015* 0.102
Well-deﬁned 1 (16.7) 5 (83.3)
Architecture
Tubular
Present 6 (54.5) 5 (45.5) — —
Absent 0 0
Glandular
Present 6 (54.5) 5 (45.5) — —
Absent 0 0
Papillary
Present 6 (54.5) 5 (45.5) — —
Absent 0 0
Retiform
Present 6 (54.5) 5 (45.5) — —
Absent 0 0
Glomeruloid
Present 4 (57.1) 3 (42.9) 1.000 —
Absent 2 (50.0) 2 (50.0)
Sex cord-like
Present 1 (25.0) 3 (75.0) 0.242 —
Absent 5 (71.4) 2 (28.6)
Comedonecrosis-like
Present 2 (100.0) 0 0.455 —
Absent 4 (44.4) 5 (55.6)
Sarcomatous component
Present 3 (75.0) 1 (25.0) 0.545 —
Absent 3 (42.9) 4 (57.1)
Extrauterine extension
Present 4 (100.0) 0 0.061 —
Absent 2 (28.6) 5 (71.4)
Invasion depth
EM-SM 5 (62.5) 3 (37.5) 0.545 —
DM-PM 1 (33.3) 2 (66.7)
FIGO stage
III-IV 5 (100.0) 0 0.015* 0.046*
I-II 1 (16.7) 5 (83.3)
Nuclear atypia
Severe 3 (75.0) 1 (25.0) 0.545 —
Mild to moderate 3 (42.9) 4 (57.1)
Coagulative tumor cell necrosis
Present 6 (85.7) 1 (14.3) 0.015* 0.102
Absent 0 4 (100.0)
Mitosis
> 10/10 HPFs 6 (100.0) 0 0.002* 0.025*
≤ 10/10 HPFs 0 5 (100.0)
Lymphovascular invasion
Present 6 (85.7) 1 (14.3) 0.015* 0.046*
Absent 0 4 (100.0)
HPFs indicates high-power ﬁelds.
*Statistically signiﬁcant.
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TABLE 4. Immunophenotype of UB-MNAC
Case GATA3 PAX2 PTEN ER PR p53 p16 CD10 Calretinin CK7
1 NA NA NA NA NA NA NA NA NA NA
2 NA NA NA Negative Negative Wild-type pattern NA Positive (luminal) NA Positive
3 NA NA NA Negative Negative Wild-type pattern NA Positive NA Positive
4 NA NA NA NA NA NA NA Positive Positive (focal) NA
5 NA NA NA Negative Negative NA NA Negative Positive NA
6 NA NA NA Negative Negative Wild-type pattern NA Positive (luminal) Positive (focal) NA
7 NA NA NA Negative Negative NA NA Positive (luminal) Positive NA
8 NA NA NA Negative Negative NA NA Positive (luminal) Positive NA
9 NA Positive NA Negative Negative Wild-type pattern NA Positive (luminal) Negative Positive
10 NA NA NA Negative Negative NA NA Positive Positive NA
11 NA NA NA Negative Negative Wild-type pattern NA Positive Negative NA
12 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
13 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Positive (focal) Positive
14 Positive (focal) Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Positive (focal) Positive
15 Positive (focal) Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
16 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
17 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
18 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
19 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
20 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
21 Positive (focal) Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Negative Positive
22 Positive Positive Positive Negative Negative Wild-type pattern Negative (patchy) Positive (luminal) Positive (focal) Positive
CK7 indicates cytokeratin 7; NA, not applicable.
FIGURE 4. Immunostaining results of UB-MNAC. A, Uniform nuclear GATA3 expression. B, Diffuse and strong nuclear PAX2
immunoreactivity. C, Preserved PTEN expression. D, Lack of ER expression. E, Lack of PR expression. F, Wild-type p53 immunostaining
pattern. G, Focal p16 expression. H, Uniform CD10 immunoreactivity along the luminal surface. I, Focal calretinin expression.
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hyalinization, in addition to positive immunoreactivity for
GATA3 and PAX2, helps to exclude the possibility of clear
cell carcinoma.
The diagnosis of UB-MNAC on the basis of endometrial
curettage is complicated, as these specimens may include only
part of the tumor tissue, showing only a single growth pattern.
Upon review of 8 curettage specimens from our cohort, 3 cases
displayed >1 architectural pattern, whereas 5 specimens had
only the glandular pattern. In these cases, it was almost im-
possible to differentiate UB-MNAC from endometrioid carci-
noma without additional immunohistochemical staining data.
However, we doubt that immunostaining should be performed
in all curettage specimens exhibiting malignant tumors
with glandular differentiation to exclude the possibility of
UB-MNAC. This is a cost-effect issue, as UB-MNAC is
extremely rare.
We investigated the relationship between the develop-
ment of metastasis and 11 pathologic characteristics of UB-
MNAC. Large tumor size, ill-deﬁned tumor border, advanced
FIGO stage, presence of coagulative tumor cell necrosis, high
mitotic activity, and presence of lymphovascular invasion were
signiﬁcantly associated with the development of metastasis.
In addition, in multivariate regression, advanced FIGO stage,
high mitotic activity, and lymphovascular invasion were
identiﬁed as independent factors predicting the development of
metastasis. The statistical signiﬁcance of analyses using 22 cases
including 11 previously reported cases was consistent with that
using our 11 cases (Supplementary Table 2, Supplementary
Digital Content 1, http://links.lww.com/PAS/A567). These
ﬁndings suggest that pathologic characteristics conventionally
used for the prognostication of patients with endometrial
carcinoma are also valuable in classifying patients with
UB-MNAC into high-risk and low-risk groups for metastasis.
A signiﬁcant relationship between the presence of sarcomatous
component and aggressive biological behavior has been sug-
gested in UC-MNAC.9 However, this seemed not the case
based on our cohort. In fact, our observation that metastatic
tumor tissues consisted solely of carcinomatous component
(exclusively of glandular pattern) attests against a relationship
between the presence of sarcomatous component and meta-
stasis. There is no standard grading system for nuclear atypia of
MNAC. In this study, the degree of nuclear atypia determined
based on the FIGO grading system for endometrioid carcino-
ma did not show a signiﬁcant relationship with metastasis.
It has been reported thatMNAC nuclear features in most cases
would be graded 2 to 3 by the FIGO grading system, but are
not classic grade 3 nuclei.5 To our experience and that of other
authors, the FIGO grading system may not appropriately
reﬂect the severity of UB-MNAC.
The molecular pathogenesis and driver-mutation proﬁle
of MNAC remain largely unknown. In this study, analyses of
NGS data revealed that 10/12 cases of UB-MNAC harbored
activating KRAS mutation. This ﬁnding is consistent with
previous observations by Mirkovic et al,20 who reported acti-
vating KRAS and NRAS mutations in 12/17 and 1/17 cases of
MNAC, respectively. Considering that the majority (12/17) of
tumor samples in their report were of cervical origin, KRAS
mutation appears to be a driver mutation in MNAC of either
FIGURE 5. Summary of SNVs identified in 12 UB-MNACs by NGS. Each column represents a case, and each row represents a gene.
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UC or corpus. In addition, we found that 9/12 cases harbored
ARID1A mutation. In line with this ﬁnding, Mirkovic et al20
reported ARID1A mutation in 6/17 cases. The most common
ARID1Amutation in UB-MNAC was T294P, which has been
also reported in endometrial endometrioid carcinoma, serous
carcinoma, and carcinosarcoma.31 Two ARID1A mutations
(Q288P and Q287Pfs) identiﬁed in this study were novel
missense mutations.
Gain of 1q was the most common CNV, detected in
11/12 UB-MNACs. This ﬁnding is in agreement with that
of Mirkovic et al,20 who detected 1q gain in 12/17 cases of
MNAC. In fact, 1q gain is the most common chromosomal
FIGURE 6. Summary of CNVs identified in 12 UB-MNACs by NGS. Each column represents a case, and each row represents a chromosome.
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alteration across all types of endometrial carcinoma.32 We
found 1p loss in 2/11 cases with 1q gain. This ﬁnding is
consistent with a previous report in which 2/3 cases with 1q
gain had 1p loss.20 Moreover, the fact that we identiﬁed 10q
gain exclusively in cases associated with metastasis is
consistent with the ﬁnding of Mirkovic et al20 of gain of
chromosome 10 in 3 cases with metastasis, supporting the
notion that gain of chromosome 10 may be an indicator of
aggressive biological behavior of MNAC.
One case in our cohort lacked both KRAS and ARI-
D1A mutations. Three cases of UC-MNAC lacking both of
KRAS and ARID1A mutations have been reported.20 Three
of these 4 MNACs lacking both KRAS and ARID1A
mutations exhibited 1q gain. We found that our case was the
only one arising from the UB and displaying lung metastasis.
However, we could not identify histopathologic discrim-
inators because of insufﬁcient available information on the
previously reported 3 MNACs. The nature and biological
behavior of KRAS-wild type/ARID1A-wild type MNAC
would be clariﬁed if such cases are accumulated.
In summary, we comprehensively analyzed clin-
icopathologic and molecular characteristics of UB-
MNAC. Our observations indicate that UB-MNAC dis-
plays an aggressive biological behavior, with a tendency to
metastasize to the lungs. Adverse pathologic character-
istics, including large tumor size, ill-deﬁned tumor border,
presence of coagulative tumor cell necrosis, high mitotic
activity, extrauterine extension, and presence of lympho-
vascular invasion, are likely to reﬂect the aggressive nature
of UB-MNAC. NGS data revealed distinct molecular
features of UB-MNAC, including frequent somatic mu-
tations of KRAS and ARID1A and gain of 1q.
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